AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$92.77
0.18 (0.19%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 10, 2026
9d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AZN shows positive signals but monitor for confirmation. Market pricing in 0.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: AZN shows positive signals but monitor for confirmation. Market pricing in 0.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$136.20
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$84.57
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $92.77, which is considered fair relative to its 30-day fair value range of $91.56 to $94.65. The stock's valuation (Forward PE: 18.1) is in line with its historical norms (18.2). Remarkably, the market is currently pricing in an annual earnings decline of 0.3% over the next few years. This pessimistic expectation contrasts with the company's recent 78.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, AZN is in a strong uptrend. Immediate support is located at $89.04, while resistance sits at $96.18.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AZN is in a strong uptrend. Immediate support is located at $89.04, while resistance sits at $96.18.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$91.56 -
$94.65
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
67.6%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($100.96)
Fair Price Analysis
30-Day Fair Range
$91.56 -
$94.65
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$89.04
Resistance Level
$96.18
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
18.07
Wall Street Target
$100.96
(+9.0%)
Revenue Growth (YoY)
12.0%
Earnings Growth (YoY)
78.0%
Profit Margin
16.2%
Valuation Discount vs History
-0.3% cheaper
PE vs Historical
18.1 vs 18.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.3%
(market-implied from PE analysis)
1-Year Target
$92.31
(0%)
2-Year Target
$92.04
(-1%)
3-Year Target
$91.76
(-1%)
3-Yr Target (if PE normalizes)
(PE: 18→18)
$92.44
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 11.8%)
$159.75
(+73%)
Base:
(SPY PE: 18.1, Growth: 11.8%)
$129.42
(+40%)
Bear:
(PE: 15.4, Growth: 11.8%)
$110.00
(+19%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 30.97 | Current EPS (TTM): $3.01
Bull Case
$174.60
(+88%)
Analyst growth 70.3%, PE expands to 34.1
Base Case
$158.73
(+71%)
Market implied 70.3%, PE stable at 31.0
Bear Case
$63.39
(-32%)
Severe decline -20.0%, PE contracts to 26.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.1 to 18.2
Stabilization Target:
$93.28
(+0.7%)
PE Expansion Potential:
+0.7%
Last updated: January 30, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$192 | 58 HOLD |
Advanced AZN Option Strategies
Professional options setups generated by AI based on today's AZN price and gamma walls.
